AB0410 COMPARISON OF ON-LABEL TREATMENT PERSISTENCE IN REAL-WORLD PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB VERSUS SUBCUTANEOUS TNF INHIBITORS

N J Shiff,N J Shiff,J A Walsh,I Lin,R Zhao,L Morrison,B Emond,L H Yu,S Schwartzbein,P Lefebvre,D Pilon,S D Chakravarty,S D Chakravarty,P J Mease,P J Mease

doi:10.1136/annrheumdis-2024-eular.2234

AB0410 COMPARISON OF ON-LABEL TREATMENT PERSISTENCE IN REAL-WORLD PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB VERSUS SUBCUTANEOUS TNF INHIBITORS

N J Shiff, N J Shiff + Show 13 more

https://doi.org/10.1136/annrheumdis-2024-eular.2234

Copy DOI

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2024

#Psoriatic Arthritis #United States Food And Drug Administration + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Background:In psoriatic arthritis (PsA), treatment persistence is important for achieving optimal outcomes. The United States Food and Drug Administration (USFDA) approved guselkumab (a fully human interleukin [IL]-23p19-subunit inhibitor) for the...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.